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Abstract
Background: Cryptococcal infection is a common opportunistic infection among severely immunosuppressed HIV
patients and is associated with high mortality. Positive cryptococcal antigenemia is an independent predictor of
cryptococcal meningitis and death in patients with severe immunosuppression. We evaluated the prevalence and
factors associated with cryptococcal antigenemia among patients with CD4 counts of 100 cells/mm
3 or less in
Mulago Hospital, Kampala, Uganda. Screening of a targeted group of HIV patients may enable early detection of
cryptococcal infection and intervention before initiating antiretroviral therapy. Factors associated with cryptococcal
antigenemia may be used subsequently in resource-limited settings in screening for cryptococcal infection, and
this data may also inform policy for HIV care.
Methods: In this cross-sectional study, HIV-infected patients aged 18 years and older with CD4 counts of up to
100 cells/mm
3 were enrolled between December 2009 and March 2010. Data on socio-demographics, physical
examinations and laboratory tests were collected. Factors associated with cryptococcal antigenemia were analyzed
using multiple logistic regression.
Results: We enrolled 367 participants and the median CD4 count was 23 (IQR 9-51) cells/mm
3. Sixty-nine (19%) of
the 367 participants had cryptococcal antigenemia. Twenty-four patients (6.5%) had cryptococcal meningitis on
cerebrospinal fluid analysis and three had isolated cryptococcal antigenemia. Factors associated with cryptococcal
antigenemia included: low body mass index of 15.4 kg/m
2 or less (adjusted odds ratio, AOR = 0.5; 95% CI 0.3-1.0),
a CD4+ T cell count of less than 50 cells/mm
3 (AOR = 2.7; 95% CI1.2-6.1), neck pain (AOR = 2.3; 95% CI 1.2-4.6),
recent diagnosis of HIV infection (AOR = 1.9; 95% CI 1.1-3.6), and meningeal signs (AOR = 7.9; 95% CI 2.9-22.1).
However, at sub-analysis of asymptomatic patients, absence of neck pain (AOR = 0.5), photophobia (AOR = 0.5)
and meningeal signs (AOR = 0.1) were protective against cryptococcal infection.
Conclusions: Cryptococcal antigenemia is common among severely immunosuppressed HIV patients in Mulago
Hospital, Kampala, Uganda. Independent predictors of positive serum cryptococcal antigenemia were CD4
+ T cell
counts of less than 50 cells/mm, low body mass index, neck pain, signs of meningeal irritation, and a recent
diagnosis of HIV infection. Routine screening of this category of patients may detect cryptococcosis, and hence
provide an opportunity for early intervention. Absence of neck pain, photophobia and meningeal signs were
protective against cryptococcal infection compared with symptomatic patients.
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Cryptococcosis is a common and serious infection in
patients with advanced human immunodeficiency virus
(HIV) infection. Recent estimates suggest that there are
about 1 million new cases of cryptococcosis and at least
500,000 deaths annually worldwide due to HIV-associated
cryptococcosis [1]. The vast majority of cases occur among
patients living in sub-Saharan Africa. The rate of crypto-
coccal infection in Uganda was 40.4 cases per 1,000 person
years and 1.5 cases per 1,000 person years in the pre-highly
active antiretroviral therapy (HAART) and HAART period,
respectively [2]. In more affluent countries, the incidence
of HIV-associated cryptococcosis has decreased dramati-
cally [3], and early mortality associated with this disease is
generally under 10%. Among patients who die early upon
antiretroviral therapy (ART) initiation, cryptococcal disease
is the second most common cause of death after tuberculo-
sis [4]. A cohort in Uganda showed a 14-day mortality rate
of 20% to 42% among patients with cryptococcal meningi-
tis (CM) despite treatment with Amphotericin B [5].
In areas of high incidence of cryptococcal disease, pri-
mary antifungal prophylaxis is shown to be effective in
reducing the incidence of CM [6]. Cost effectiveness of
prophylaxis was found at $511 per life year gained[7]. The
best prophylaxis is rapid immune reconstitution with
ART. However, in areas of high incidence of CM, screen-
ing for cryptococcosis prior to ART initiation is necessary
for potential early diagnosis and treatment. This could
decrease the risk of immune inflammatory syndrome [8,9].
In Cambodia and South Africa, screening for cryptococ-
cal antigenemia in HIV-infected patients with advanced
HIV infection predicted mortality and incidence of CM.
The prevalence of cryptococcal antigenemia was 18% [10]
and 13% [11], respectively. The majority of HIV-infected
patients in resource-limited settings present late with
advanced immunosuppression.
In this study, we screened HIV-infected patients with
C D 4c o u n t so fu pt o1 0 0c e l l s / m m
3 at Mulago Hospital,
Kampala, Uganda, to determine the prevalence and factors
associated with cryptococcal antigenemia. The serum
cryptococcal antigen test has been found to be cost effec-
tive in preventing deaths in HIV patients with severe
immunosuppression [12]. Screening of a targeted group of
HIV patients may enable early detection of cryptococcal
infection and intervention before initiating ART. This
study will, therefore, inform guidelines for screening, diag-
nosis and treatment of cryptococcal infection among
severely immunosuppressed HIV-infected patients in
resource-limited settings.
Methods
HIV care and treatment in Mulago Hospital, Uganda
We conducted a cross-sectional study involving both
inpatients and outpatients at the 1,500-bed Mulago
National Referral and Teaching Hospital, in Kampala,
Uganda. Study participants were enrolled from the med-
ical wards and the HIV outpatient clinic between
December 2009 and March 2010. Routine counselling
and testing for HIV and CD4 count testing are offered
in the hospital through PEPFAR support under the
Makerere Mbarara Joint AIDS Program on a daily basis
in the medical wards. The HIV outpatient clinic is
located on the same floor as the medical wards. The
clinic provides ART, prophylaxis and management of
opportunistic infections, CD4 count testing and other
investigations.
Study design and patients
Patients were only approached to participate in the study if
they were HIV positive and had CD4 results that were less
than six months old. All HIV-infected adults on the medi-
cal wards and patients referred to the outpatient HIV
clinic for their first visit were screened and gave informed
consent to participate in the study. For very sick patients,
informed consent was obtained from the next of kin.
Patients were enrolled if they had CD4
+ counts of
100 cells/mm
3 or less, no prior history of cryptococcosis,
were not receiving fluconazole treatment, and were ART
naïve. A questionnaire was used to collect data on socio-
demographics and medical history. A detailed physical
examination was performed. Clinical signs of meningitis
were categorized as neck stiffness, altered mental status or
neurological deficits.
This study was reviewed and approved by the Maker-
ere School of Medicine Research and Ethics Committee
and the Uganda National Council for Science and
Technology.
Definitions
Severe immunosuppression was defined as a CD4+
T cell count of 100 cells/mm
3 or less. Cryptococcal anti-
genemia was defined as having a positive serum Crypto-
coccal antigen test. Cryptococcal meningitis was defined
as having one of the following: symptoms and signs of
meningitis with a positive CRAG test, positive India ink
or serum and cerebrospinal fluid (CSF) culture of
C. neoformans. Isolated cryptococcal antigenemia was
defined by only positive serum cryptococcal antigen by
latex agglutination test with negative culture in CSF or
negative CSF cryptococcal antigen by latex agglutination
test.
Meningeal signs were defined as resistance to knee
extension with both knee and hip flexed while the
patient was supine, and nuchal rigidity.
Laboratory assays
CSF or serum cryptococcal antigen was detected using a
latex agglutination test (Wampole Laboratories Crypto-LA
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instructions at the Faculty of Medicine Laboratory, Maker-
ere University. Briefly, the specimens’ serum or CSF were
screened with the detacher enzyme and incubated in tubes
at 56°C for 30 minutes. Then, the enzyme inhibitor was
added, and the specimen was applied on the agglutination
slide and then mixed with anti-cryptococcal latex. The
slide was placed on the rotator at 100 revs/minute for five
minutes. The reactions were graded as follows: negative
result was indicated by a smooth, milky suspension with
absence of agglutination; and positive result was indicated
as distinct large clumps against a clear or slightly milky
background, or small definite clumps against a milky
background.
The test kit included a pronase and has been shown to
have a sensitivity of 93% to 100% and a specificity of 96%
to 98% [13]. CSF specimens for culture of Cryptococcus
neoformans were centrifuged and the sediment inocu-
lated onto Sabouraud’s dextrose agar and incubated at
30°C for 14 days. The suspected colonies were identified
by standard methods [14].
Statistical methods
All analyses were performed using STATA 10.0 (Texas,
USA) program. Medians and frequencies (%) were used
to describe patients’ characteristics. Fisher’se x a c tt e s t
was used to compare categorical variables where appro-
priate. Student’s t-test was performed to assess the differ-
ences between the two means. Binary logistic regression
was used to determine factors associated with positive
serum cryptococcal antigen. Factors that were signifi-
cantly associated with positive serum cryptococcal anti-
gen at bivariate analyses were entered into a multiple
logistic regression to determine their independent asso-
ciation. For strength of association, adjusted odds ratios
and a p value of ≤ 0.05 were considered significant.
Results
Patients’ characteristics at admission and initial contact in
the clinic
Between November 2009 and March 2010, 1,146 HIV-
positive patients were screened at Mulago Hospital,
Uganda. Only 370 of the patients screened met the eligibil-
ity criteria (see Figure 1). In all, 367 patients with a median
CD4
+ count of 23 (IQR 9-51) cells/mm
3 were enrolled (see
Table 1). The median age of the patients was 32 (IQR 28-
39) years. There were slightly more female (52%) than
male (48%) patients. The majority of participants were
married (45%), had attained primary education (52%), and
lived in urban areas (77%). A total of 97.3% participants
were inpatients and 2.7% were outpatients. A median
duration in days of presenting symptoms were as follows:
cough 30 (IQR 21-60), headache 14 (IQR 7-30), vomiting
7 (IQR 3-21), neck pain 7 (IQR 5-14), confusion 7 (IQR
3-7), photophobia 7 (IQR 5-14), papular rash 90 (IQR 60-
180) and convulsion 2 (IQR 2-7) (see Figure 2).
Prevalence and factors associated with cryptococcal
antigenemia
The prevalence of cryptococcal antigenemia among HIV-
infected adults with CD4 counts of up to 100 cells/mm
3
was 19% (69 of 367) (95% CI 0.15-0.23) in this study. At
bivariate analysis the presence of headache, neck pain,
convulsions, photophobia, meningeal irritation signs,
WHO stage III and IV, altered mentation and CD4
counts of less than 50 cells/mm
3 were significantly asso-
ciated with cryptococcal antigenemia. Refer to Table 2
for analysis of asymptomatic patients with positive serum
cryptococcal antigenemia.
Factors independently associated with positive serum
cryptococcal antigenemia included: low body mass index
(BMI) of 15.4 kg/m
2 or less (adjusted odds ratio, AOR =
0.5; 95% CI 0.3-1.0), a CD4+ T cell count of less than
50 cells/mm
3 (AOR = 2.7; 95% CI1.2-6.1), neck pain
(AOR = 2.3; 95% CI 1.2-4.6), recent diagnosis of HIV
infection (AOR = 1.9; 95% CI 1.1-3.6), and meningeal
signs (AOR = 7.9; 95% CI 2.9-22.1).
However, sub-analysis of asymptomatic patients with
positive serum cryptococcal antigenemia demonstrated
that absence of neck pain (AOR = 0.5), photophobia
(AOR = 0.5) and meningeal signs (AOR = 0.1) were pro-
tective against cryptococcal infection (see Table 3).
Further microbiological tests were done in patients
with positive serum cryptococcal antigenemia as standard
of care. Lumbar punctures were performed to exclude
cryptococcal meningitis in patients with positive serum
cryptococcal antigen tests. However, only 43.5% of the
patients consented to having lumbar punctures. The rest
did not have lumbar puncturesf o rv a r i o u sr e a s o n s :r a n
away (one), comatose (one), discharged (18), died (six),
and declined (13). India ink, cultures for Cryptococcus
neoformans and CSF CRAG were performed. Tests done
showed 24 patients had cryptococcal meningitis, three
h a di s o l a t e dc r y p t o c o c c a la ntigenemia, and three could
not be classified because of incomplete results. Patients
with cryptococcal meningitis were hospitalized for treat-
ment with Amphotericin B. Three patients diagnosed
with isolated cryptococcal antigenemia were treated with
oral fluconazole (200 mg/day) for 12 weeks. Treatment
was given as routine care. No follow up was carried out.
Discussion
The results from our study demonstrate a high prevalence
(19%) of cryptococcal antigenemia in an urban setting
among HIV-infected patients with severe immunosuppres-
sion. This prevalence is comparable to findings in Cambo-
d i a[ 1 0 ] .I nac o m m u n i t yc l i n i ci nar u r a ls e t t i n gi n
Tororo, Uganda, a prevalence of only 5.3% was reported.
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most likely because only patients who were asymptomatic
participated in the study [15]. The high prevalence in our
study warrants the need to screen for and diagnose crypto-
coccal infection among patients with severe immunosup-
pression prior to initiation of ART. This may prevent
unmasking of sub-clinical infection, especially in patients
who are asymptomatic [16].
Screening for serum cryptococcal antigen is highly
sensitive, specific and cost effective in preventing death
in HIV-infected patients with CD4 counts of 100 cells/
mm
3 or less [12]. Cost effectiveness analysis in Uganda
Figure 1 Study profile.
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CRAG screening and fluconazole treatment to prevent
one CM case is 11.3 (95% CI 7.9-17.1) at a cost of US
$190 (95% CI, $132-$287) while the number needed to
test and treat to save one life is 15.9 (95% CI 11.1-24.0)
at a cost of $266 (95% CI $185-$402) [12].
Several cohorts in sub-Saharan Africa have reported
high early mortality and immune reconstitution inflam-
matory syndrome after ART initiation [4,16]. In one
cohort, a high early mortality rate of 14% during the first
year of therapy, particularly during the first three months,
was reported [4]. Tuberculosis and cryptococcal disease
accounted for at least one-third of all HIV-related deaths.
Cryptococcal antigen test is available in a few centres in
Uganda and is also very expensive. If this test is made
widely available and rolled out as part of HIV care policy,
batch testing of samples could be done with a reduction
in costs, and thus making it affordable to ensure timely
initiation of appropriate management for cryptococcal
infection.
The following factors were independently associated
with cryptococcal antigenemia: severe immunosuppression
with CD4 counts of less than 50 cells/mm
3, low BMI with
less than 15.4 kg/m
2, meningeal signs, neck pain, and hav-
ing a recent diagnosis of HIV infection. And asymptomatic
patients are more protected against cryptococcal infection,
as seen in the analysis. This is the category of patients who
may benefit from primary prophylaxis.
Patients with CD4 counts of less than 50 cells/mm
3
were more likely to have cryptococcal antigenemia (23%
compared with 8% of patients with CD4 counts of more
Table 1 Baseline characteristics of the patients at
enrolment
Characteristics Frequency (%) N = 367
Age median (IQR) in years 32 (28 to 39)
Sex
Males 177(48.2)
Females 190(51.8)
Residence
Urban 283(77.1)
Rural 84(22.9)
BMI kg/m
2
> 15.4 295(80.4)
≤ 15.4 72(19.6)
Karnofsky score
60-100 286(77.9)
≤ 50 81(22.1)
Meningeal signs present 24(6.5)
Presence of focal neurological deficits 10(2.7)
Papular rash 27(7.4)
WHO stage
I 14(3.8)
II 47(12.8)
III 174(47.4)
IV 132(36.0)
HIV status
Previously known 236(64.3)
Recent HIV diagnosis 131(35.7)
CD4 (cells/mm
3)
Median (IQR) 23 (9 to 51)
50-100 98(26.7)
< 50 269(73.3)
Figure 2 Common symptoms among study patients (n = 367) screened for serum cryptococcal antigenemia at Mulago Hospital,
Kampala.
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3). This finding is similar to that
reported by Micol et al [10]. Low CD4
+ cell counts pre-
dispose these patients to cryptococcal infection because
of dysfunctional immune systems. In a resource-limited
setting, screening of patients with CD4
+ counts of less
than 50 cells/mm
3 for cryptococcal infection may even
be more clinically relevant as CD4 tests become more
available.
Primary fluconazole prophylaxis among HIV-infected
patients is known to be beneficial in preventing crypto-
coccal disease; however, it is more logical and cost effec-
tive to offer targeted intervention with fluconazole for
severely immunosuppressed and asymptomatic patients
testing positive for cryptococcal antigen [6]. This study
has demonstrated that asymptomatic patients are pro-
tected against cryptococcal infection compared with
symptomatic patients.
In this study, low BMI was independently associated
with positive serum CRAG. Malnutrition predisposes to a
dysfunctional immune system [17], which could have also
predisposed patients to the risk of cryptococcal infection.
The following findings have been reported in malnour-
ished HIV-infected patients: suppression of antigen spe-
cific arms of immune system and several generalized host
defense mechanisms, including decreased T cell primary
antibody response, memory response and atrophy of
lymph tissues [18]. Peripheral lymphocytes and natural
killer cells activities have also been found to be reduced
in these patients. Low BMI (under 15.4 kg/m
2)w a s
reported to be an independent factor associated with
cryptococcal antigenemia in Cambodia [10].
One-quarter of the patients with cryptococcal antige-
nemia had signs of meningeal irritation in our study.
The majority of patients with meningeal signs (14 of 17)
had CM. Although serum CRAG identifies cryptococcal
infection, presence of meningeal signs and neck pain
indicates CM. French et al noted that cryptococcal anti-
genemia preceded symptoms of CM by a median dura-
tion of 22 days [2]. Neck pain was also found to be
independently associated with cryptococcal antigenemia
in our study. Neck pain is probably a continuum of
meningeal irritation in our patients. The majority of
patients with neck pain (22 of 28 or 78.6%) had CM.
Severe immunosuppression predisposed these patients
to developing stage IV AIDS events.
Nearly half of the patients with cryptococcal antigene-
mia were newly diagnosed with HIV infection. Patients
in our setting still continue to present for the first time
with severe immunosuppression and life-threatening
events. In a South African cohort, 25 patients (54%) pre-
sented with incident cryptococcal antigenemia prior to
ART initiation [11]. The need to increase routine coun-
selling and testing in our setting cannot be overempha-
sized as it offers the opportunity for early screening of
cryptococcal infection and other opportunistic infections
and thus targeted interventions that in the long run off-
set the high costs of managing full-blown infections and
possibly death.
Headache was found to be insignificant in this study.
Culturally, in our setting, headache may be perceived as
a state of being unwell. Other co-morbidities could have
also presented as headache.
Table 2 Bivariate analysis of asymptomatic participants by serum CRAG
Characteristics Serum CRAG-negative patients
(n = 298)
Serum CRAG-positive patients
(n = 69)
Crude odds
ratio
95% CI p value
Residence 230(77.2) 53(76.8) 1.0 0.6-1.9 0.95
Urban Rural
Symptoms
68(22.8) 16(23.2)
Neck pain absent 256(85.9) 41(59.4) 0.2 0.1-0.4 0.00
Seizures absent 286(95.9) 61(88.4) 0.3 0.1-0.8 0.02
Photophobia absent 267(89.6) 46(66.7) 0.2 0.1-0.4 0.00
Physical signs
Meningeal signs
absent
291(97.7) 52(75.4) 0.1 0.0-0.2 0.00
* Significant at p ≤ 0.05 level
Table 3 Multivariate analysis: Factors associated with asymptomatic positive cryptococcal antigenemia
Variables Unadjusted OR Adjusted OR 95% CI p value
Meningeal signs absent 0.1 0.1 0.1-0.4 0.00
Photophobia absent 0.2 0.5 0.2-1.0 0.05
Seizures absent 0.3 0.9 0.3-2.9 0.79
Neck pain absent 0.2 0.5 0.2-1.0 0.05
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Our study has shown that almost 20% of severely immu-
nosuppressed HIV-infected patients have positive serum
cryptococcal antigenemia. Clinicians should be more
vigilant in screening for cryptococcal disease among
HIV-infected patients with low CD4 counts (less than
50 cells/mm
3), presence of meningeal irritation, neck
pain, a low BMI (less than 15.4 kg/m
2), and a recent HIV
diagnosis before ART initiation for appropriate interven-
tion. And asymptomatic patients are more protected
against cryptococcal infection than symptomatic patients.
This is the category of persons who may benefit from
primary antifungal prophylaxis.
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